Possible net harms of breast cancer screening: updated modelling of Forrest report OPEN ACCESS
نویسندگان
چکیده
Objective To assess the claim in a Cochrane review that mammographic breast cancer screening could be doing more harm than good by updating the analysis in the Forrest report, which led to screening in the United Kingdom. Design Development of a life table model, which replicated Forrest’s results before updating and extending them with data from relevant systematic reviews, trials, and other models based on purposive literature searches. ParticipantsWomen aged 50 and over invited for breast cancer screening. Main outcomemeasuresQuality adjusted life years (QALYs), combining life years gained from screening with losses of quality of life from false positive diagnoses and surgery. Results Inclusion of the effects of harms reduced the updated estimate of net cumulative QALYs gained after 20 years from 3301 to 1536 or by more than half. The best estimates from the Cochrane review generated negative QALYs for the first seven years of screening, 70 QALYs after 10 years, and 834 QALYs after 20 years. Sensitivity analysis showed these results were robust to a range of assumptions, particularly up to 10 years. It also indicated the importance of the level and duration of harms from surgery. Conclusions This analysis supports the claim that the introduction of breast cancer screening might have caused net harm for up to 10 years after the start of screening.
منابع مشابه
To screen or not to screen for breast cancer? How do modelling studies answer the question?
Breast cancer screening is a topic of hot debate, and currently no general consensus has been reached on starting and ending ages and screening intervals, in part because of a lack of precise estimations of the benefit-harm ratio. Simulation models are often applied to account for the expected benefits and harms of regular screening; however, the degree to which the model outcomes are reliable ...
متن کاملConvergence and Divergence Around Breast Cancer Screening.
I 2015, contentious discussions about breast cancer screening and prevention continued, with physicians, advocates, lawmakers, and scientists all lending their voices to the debate. Many of these stakeholders focused on the need for women to be able to make more informed health care choices about when to start screening without having to worry about the cost of an insurance copayment. The role ...
متن کاملCounseling Women About Breast Cancer Screening.
Breast cancer is one of the most common malignancies among women, with approximately 3% of women dying from the disease and approximately 12% of those who live to 80 years of age being diagnosed with it at some point during their lifetime.1 Although screening mammography reduces breast cancer–specific mortality, women may overestimate its benefit.2 Biennial mammography is recommended for all wo...
متن کاملComparative study of chemo-sensitivity expressed as micronuclei in lymphocytes of breast cancer patients, their unaffected first degree relatives and normal controls as a possible prognostic marker
Background: Genomic instability is one of primary causes for malignant cell transformation. In this study induced genomic instability expressed as micronuclei in breast cancer (BC) patients with different stages of the disease compared with their unaffected first degree relatives (FDR) and normal unrelated controls was investigated. Materials and Methods: The background and net micronucleus fre...
متن کاملACS releases updated guidelines on cancer screening.
Breast Cancer Early detection of breast cancer in average-risk women includes a combination of regular clinical breast examination and counseling, and mammography. Women between 20 and 39 years of age should undergo clinical breast examination every three years, and then annually beginning at 40 years of age. During clinical breast examination, physicians should discuss with patients the import...
متن کامل